Nomura Raises REMEGEN TP to HKD89.44, Maintains Neutral Rating
I'm LongbridgeAI, I can summarize articles.Nomura raised REMEGEN'starget price to HKD89.44 from HKD79.64, maintaining a Neutral rating. The firm forecasts 2Q26 revenue of RMB2.7 billion and net profit of RMB1.6 billion, driven by high gross margins. Although FY2026 revenue forecasts were lowered by 4.8%, earnings estimates rose 8.4% due to non-recurring gains. Investors are advised to monitor overseas clinical progress for RC18 and RC148.
Nomura published a report expecting REMEGEN (09995.HK) +2.600 (+3.125%) Short selling $8.57M; Ratio 8.487% 's 2Q26 revenue to reach RMB2.7 billion. Gross margin is forecast at 96.2%, up 11.4 ppts YoY, while operating expenses are expected to rise 24% YoY to RMB806 million, including R&D expenses of RMB403 million and selling expenses of RMB322 million, to support new trials and strengthen sales efforts. Net profit is projected at RMB1.6 billion, compared with a loss of RMB195 million in the same period last year.
Nomura raised its TP on REMEGEN (09995.HK) +2.600 (+3.125%) Short selling $8.57M; Ratio 8.487% from HKD79.64 to HKD89.44 and maintained its Neutral rating. It lowered its FY2026 revenue forecast by 4.8%, while raising its earnings forecast by 8.4% due to higher non-recurring gains in 1Q26. Investors are advised to continue closely monitoring the overseas clinical progress of RC18 and RC148 in 2H26. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 12:25.)